Synopsys, Inc. $SNPS Shares Newly Acquired by BNP Paribas

BNP Paribas purchased a new position in shares of Synopsys, Inc. (NASDAQ:SNPS – Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 70,658 shares of the semiconductor company’s stock, valued at approximately $29,981,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Whittier Trust Co. raised its position in Synopsys by 2.9% in the 3rd quarter. Whittier Trust Co. now owns 847 shares of the semiconductor company’s stock valued at $368,000 after purchasing an additional 24 shares in the last quarter. Elevation Wealth Partners LLC raised its stake in shares of Synopsys by 96.4% during the second quarter. Elevation Wealth Partners LLC now owns 55 shares of the semiconductor company’s stock worth $25,000 after purchasing an additional 27 shares during the last quarter. North Dakota State Investment Board boosted its holdings in Synopsys by 0.5% in the 3rd quarter. North Dakota State Investment Board now owns 5,706 shares of the semiconductor company’s stock valued at $2,482,000 after purchasing an additional 29 shares in the last quarter. Oak Grove Capital LLC lifted its position in shares of Synopsys by 1.1% during the 3rd quarter. Oak Grove Capital LLC now owns 2,898 shares of the semiconductor company’s stock valued at $1,260,000 after acquiring an additional 32 shares during the period. Finally, Kintegral Advisory LLC raised its position in Synopsys by 0.6% during the third quarter. Kintegral Advisory LLC now owns 5,812 shares of the semiconductor company’s stock worth $2,528,000 after acquiring an additional 32 shares during the last quarter. 85.47% of the stock is currently owned by hedge funds and other institutional investors.

Key Synopsys News

These are some of the SNPS news items that stood out recently:

  • Positive Sentiment: Barclays initiated coverage with an Overweight rating and a $640 price target, citing Synopsys’ leadership in electronic design automation, AI-related R&D tailwinds and long-term free-cash-flow potential. The bullish call was accompanied by a gain in Thursday trading. Barclays starts Synopsys at Overweight
  • Positive Sentiment: Synopsys-backed Ansys is supporting an integration between Instem’s toxicology tools and its simulation platform, extending the company’s reach into packaging safety and materials-risk workflows. This could broaden use of its simulation ecosystem, though the financial impact is not specified. Synopsys broadens platform reach
  • Neutral Sentiment: Synopsys is described as having stronger forward growth and a lower forward valuation multiple than Cadence, but Cadence is credited with a stronger balance sheet and returns on capital. Synopsys vs. Cadence

Insider Activity

In other news, CEO Sassine Ghazi sold 14,604 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $374.88, for a total value of $5,474,747.52. Following the completion of the transaction, the chief executive officer directly owned 76,865 shares in the company, valued at approximately $28,815,151.20. The trade was a 15.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Aart de Geus sold 25,000 shares of the company’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $441.76, for a total value of $11,044,000.00. Following the completion of the transaction, the insider directly owned 120,421 shares of the company’s stock, valued at approximately $53,197,180.96. The trade was a 17.19% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 117,163 shares of company stock valued at $51,366,457 in the last 90 days. 0.56% of the stock is owned by corporate insiders.

Synopsys Trading Down 8.0%

NASDAQ SNPS opened at $396.55 on Friday. Synopsys, Inc. has a one year low of $362.55 and a one year high of $539.48. The stock’s 50-day moving average is $448.46 and its 200-day moving average is $440.14. The firm has a market cap of $76.00 billion, a P/E ratio of 70.06, a P/E/G ratio of 1.26 and a beta of 1.18. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.34 and a quick ratio of 1.24.

Synopsys (NASDAQ:SNPS – Get Free Report) last released its earnings results on Wednesday, August 26th. The semiconductor company reported $3.91 earnings per share for the quarter, beating analysts’ consensus estimates of $3.67 by $0.24. Synopsys had a net margin of 11.43% and a return on equity of 6.24%. The business had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.44 billion. During the same quarter last year, the firm earned $3.39 earnings per share. The firm’s revenue for the quarter was up 42.4% compared to the same quarter last year. Synopsys has set its Q4 2026 guidance at 4.100-4.160 EPS and its FY 2026 guidance at 15.040-15.100 EPS. Sell-side analysts anticipate that Synopsys, Inc. will post 11.01 earnings per share for the current fiscal year.

Synopsys declared that its board has authorized a stock repurchase program on Monday, October 5th that allows the company to repurchase $1 billion in outstanding shares. This repurchase authorization allows the semiconductor company to repurchase up to 1.1% of its shares through open market purchases. Stock repurchase programs are typically a sign that the company’s management believes its stock is undervalued.

Analysts Set New Price Targets

SNPS has been the topic of several recent analyst reports. Needham & Company LLC increased their price objective on shares of Synopsys from $580.00 to $620.00 and gave the stock a “buy” rating in a report on Monday, October 12th. JPMorgan Chase & Co. dropped their target price on Synopsys from $650.00 to $600.00 in a research report on Thursday, August 27th. Sanford C. Bernstein began coverage on shares of Synopsys in a research note on Friday, September 25th. They issued an “outperform” rating on the stock. Rothschild & Co Redburn cut their price objective on shares of Synopsys from $560.00 to $550.00 and set a “buy” rating on the stock in a research report on Wednesday, September 23rd. Finally, HSBC lowered shares of Synopsys from a “buy” rating to a “reduce” rating in a research report on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Synopsys has an average rating of “Moderate Buy” and a consensus price target of $577.71.

View Our Latest Stock Analysis on SNPS

About Synopsys

(Free Report)

Synopsys, Inc. develops software, semiconductor intellectual property (IP) and services used to design and verify electronic systems. Its electronic design automation (EDA) tools help customers create, simulate, test and validate chips and other complex electronic products, while its IP portfolio provides reusable building blocks for semiconductor designs. The company also offers software security and quality tools that help developers identify vulnerabilities and assess applications throughout the software development process.

Further Reading

Want to see what other hedge funds are holding SNPS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Synopsys, Inc. (NASDAQ:SNPS – Free Report).

Institutional Ownership by Quarter for Synopsys (NASDAQ:SNPS)

Receive News & Ratings for Synopsys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synopsys and related companies with MarketBeat.com's FREE daily email newsletter.